<code id='6EDF400265'></code><style id='6EDF400265'></style>
    • <acronym id='6EDF400265'></acronym>
      <center id='6EDF400265'><center id='6EDF400265'><tfoot id='6EDF400265'></tfoot></center><abbr id='6EDF400265'><dir id='6EDF400265'><tfoot id='6EDF400265'></tfoot><noframes id='6EDF400265'>

    • <optgroup id='6EDF400265'><strike id='6EDF400265'><sup id='6EDF400265'></sup></strike><code id='6EDF400265'></code></optgroup>
        1. <b id='6EDF400265'><label id='6EDF400265'><select id='6EDF400265'><dt id='6EDF400265'><span id='6EDF400265'></span></dt></select></label></b><u id='6EDF400265'></u>
          <i id='6EDF400265'><strike id='6EDF400265'><tt id='6EDF400265'><pre id='6EDF400265'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:comprehensive    Page View:7647
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In